Annet Aketoko Onzia

Annet Aketoko Onzia

Auto-generated profile, based on publicly available information

Annet Aketoko Onzia

Infectious Disease Institute, Makerere University, Kampala, Uganda

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
ATAlexander Y. Trick
Alexander Y. Trick
JMJohan H. Melendez
Johan H. Melendez
FCFan-En Chen
Fan-En Chen
LCLiben Chen
Liben Chen
AOAnnet Onzia
Annet Onzia
TWTza-Huei Wang
Tza-Huei Wang
A portable magnetofluidic platform integrates nucleic acid purification and PCR to rapidly detect the pathogen causing gonorrhea in clinical samples.

1 April 2026 in BMJ Public Health
Verified
Journal Article
Open access
PDF file
AOAnnet Onzia
Annet Onzia
AMAndrew Mujugira
Andrew Mujugira
VNVivian Nakate
Vivian Nakate
JMJoseph Musaazi
Joseph Musaazi
ESEric Ssegujja
Eric Ssegujja
BCBarbara Castelnuovo
Barbara Castelnuovo
Introduction: Little is known about the burden of sexually transmitted infections (STIs) among adolescent girls and young women (AGYW) employed as domestic workers in Ugandan households. Methods: We conducted a community-based cross-sectional study from November 2023 to March 2024 to determine the prevalence and correlates of STIs among Ugandan AGYW aged 14–24 in the Kampala Metropolitan Area. Self-collected vaginal swabs were tested for Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) using GeneXpert. HIV and syphilis testing were performed using the Bioline HIV/syphilis Duo test. Correlates of STI prevalence were determined using modified Poisson regression. Results: Among 262 AGYW, median age was 20 years (IQR 18–23) and 87 (33%) had an STI: CT (27.5%), syphilis (5.7%), HIV (4.6%) and NG (1.5%). Overall, 14.9% had >1 STI. Of 12 AGYW with HIV, 3 (25%) were newly diagnosed and 6/9 had detectable viral loads (≥1000 copies/mL). In the prior 12 months, 126 (48%) had received syndromic STI treatment, but only 35 (28%) notified their partners. Additionally, 102 (39%) had used emergency contraception and 54% believed it was protective against STIs, including HIV. Factors associated with STI prevalence included non-cash compensation for domestic work (adjusted prevalence ratio (aPR) 2.26; 95% CI 1.04 to 4.92; p=0.040), lower educational attainment (aPR 1.73; 95% CI 1.16 to 2.57; p=0.007), alcohol consumption in the past 6 months (aPR 1.72; 95% CI 1.12 to 2.64; p=0.013) and transactional sex during the past 6 months (aPR 1.43; 95% CI 1.01 to 2.04; p=0.045). Conversely, self-reported sexual abuse was negatively associated with STIs (aPR 0.48; 95% CI 0.28 to 0.83; p=0.008). Conclusion: The high prevalence of undiagnosed STIs and unsuppressed HIV among AGYW domestic workers in Central Uganda highlights the urgent need to increase STI/HIV prevention, testing and treatment coverage for these underserved and vulnerable young women. Targeted interventions are needed to mitigate STI/HIV acquisition in this population.

18 June 2026 in BMC Infectious Diseases
Verified
Journal Article
Open access
AOAnnet Aketoko Onzia
Annet Aketoko Onzia
VNVivian Nakate
Vivian Nakate
BDBrenda M. Dawa
Brenda M. Dawa
BCBarbara Castelnuovo
Barbara Castelnuovo
SRSteven J. Reynolds
Steven J. Reynolds
MHMatthew M. Hamill
Matthew M. Hamill
Epidemiological data on HIV infection in male urethral discharge syndrome (UDS) in Africa are limited. We describe the prevalence of HIV and associated demographic and sociobehavioral factors among men with UDS in selected public clinics in Kampala, Uganda. Within a cross-sectional study of men seeking care for UDS from October 2019 to July 2022, we performed interviewer-administered demographic and sociobehavioral questionnaires. Point-of-care (POC) rapid sequential algorithmic HIV testing was conducted. Bivariate and adjusted multivariable log-binomial regression analyses were performed to determine factors associated with HIV. Of 450 male participants, 441(98%) were included in this analysis; 9 declined HIV testing. Median (IQR) age was 24 (22-32) years, 87% (n = 384) reported a previous HIV test. Overall, 18.4% (n = 81) were people living with HIV (PLWHIV). Of these, 86.4% and 13.6% were aged ≥ 25 and < 25 years, respectively. Overall, 8.6% (n = 7) were newly diagnosed with HIV; of those, 42.9% (n = 3) were aged < 25 years. While 94% (70/74) with known HIV reported antiretroviral therapy (ART) use, 52.9% (n = 37) had suppressed viral loads by self-report. Five of the 441 participants (1.1%) reported 'always' condom use, 45.4% (n = 200) reported transactional sex, 59.6% (n = 263) ≥ 2 sexual partners in the past six months; 46.7% (n = 206) had notified their partners of UDS symptoms. Multivariable analysis demonstrated significant associations between HIV and older age ≥ 25 years (aPR,6.35; 95% C.I., 3.44-11.75; P < 0.001), and hazardous alcohol use (aPR,1.62; 95% C.I., 1.03-2.54; P = 0.038). Almost one in five men presenting with UDS were PLWHIV, with just over half of those on ART reporting viral suppression. Older age and hazardous alcohol use were associated with HIV. Men with UDS represent a key population where HIV diagnosis, prevention, and ART adherence interventions may have a significant impact.

3 April 2026 in medRxiv
Verified
Preprint
Open access
PDF file
AOAnnet A. Onzia
Annet A. Onzia
ATAdelline Twimukye
Adelline Twimukye
JMJohan H. Melendez
Johan H. Melendez
MHMatthew M. Hamill
Matthew M. Hamill
PKPeter Kyambadde
Peter Kyambadde
RPRosalind Parkes-Ratanshi
Rosalind Parkes-Ratanshi
Introduction: The World Health Organization (WHO) recommends testing for sexually transmitted infections (STIs), but laboratory-based and rapid or point-of-care (POC) testing are often unavailable and unaffordable, especially in low-resource settings, leading to empiric (usually antibiotic) treatment. Community pharmacies (CPs) are often the first point of contact for persons with symptoms of STIs, where pharmacists dispense treatment without diagnostic testing or prescriptions. This study evaluated clients, providers, and policymakers’ perspectives on POC testing for STIs in CPs for targeted treatment. Methods: We nested a qualitative study into a study of participants seeking both STI and non-STI treatments in CPs. They were tested for HIV, syphilis, trichomonas, chlamydia, and gonorrhea using both rapid POC tests and a central reference lab. A purposive sample of 50 participants from September 2020 to June 2022 consented to participate in in-depth and key informant interviews. Data were analyzed thematically using an inductive approach. Results: Clients (n=35), health care providers (n=9), and policy makers (n=6) highlighted the benefits of POC tests for HIV and STIs at CPs, including affordability, accessibility, and ensuring convenience. The impact of POC testing for STI diagnosis and treatment was promoting behavioral change, rapid results turnaround time, leading to faster treatment access compared to conventional laboratory methods, and supporting sustainable antimicrobial resistance (AMR) control. Barriers to POC testing included a lack of awareness among clients and health workers, inadequate privacy and space, long wait times, unclear self-sample collection instructions, stigma around HIV testing, and reluctance to test for STIs beyond HIV. To address these, participant recommendations included raising STI awareness, providing more explanation of test results, increasing test access, addressing stigma, provider training, and ensuring a sustainable supply chain for testing kits. Conclusions: POC testing for STIs and HIV in CP settings was found to be highly acceptable to both pharmacy clients and providers. Integrating POC testing in CPs could be beneficial for national STI management programs. If the existing barriers are addressed, POC tests could improve accessibility to STI diagnostics and facilitate better linkage to care.

28 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
AOAnnet A. Onzia
Annet A. Onzia
AMAnna-Beatrice Magoro
Anna-Beatrice Magoro
ANAgnes B. Naggirinya
Agnes B. Naggirinya
JBJoshua Beinomugisha
Joshua Beinomugisha
MHMatthew M. Hamill
Matthew M. Hamill
RPRosalind Parkes-Ratanshi
Rosalind Parkes-Ratanshi
Introduction: Congenital syphilis (CS) remains a major cause of preventable stillbirths and neonatal deaths globally. This qualitative study explored perceptions and experiences of mothers, partners, providers, and policymakers regarding the barriers and facilitators to implementing antenatal and newborn syphilis testing and treatment in Kampala, Uganda. Methods: We conducted 15 in-depth interviews, four focus group discussions, and 16 key informant interviews between March and May 2022 with pregnant and postnatal women, male partners, health workers, traditional birth attendants, and Ministry of Health policymakers. Data were analyzed using the Consolidated Framework for Implementation Research (CFIR) in NVivo 12 and reported following the COREQ checklist. Results: Participants valued syphilis screening and treatment to protect infant health, particularly when they understood the consequences of untreated infection. Facilitators included respectful counselling, phone-based follow-up, and integration of testing into routine antenatal care. Key barriers included fear of painful injections, stigma and disclosure risk, low male-partner involvement, fragmented information systems, limited infant diagnostics, and medication stockouts. Partner notification was hindered by fears of infidelity accusations and relationship conflict. Notably, caregivers frequently refused treatment for asymptomatic infants due to misconceptions that only visibly ill children required care. Facility opportunities to strengthen the syphilis care cascade were identified such patient tracing systems and strengthened supply chains. Conclusions: Addressing CS requires community education, non-parenteral treatment alternatives, and affordable confirmatory neonatal testing. Stronger supply chains, integrated maternal-infant-partner care pathways, better-equipped health workers, male-engagement strategies, and consistent follow-up are needed to accelerate elimination of mother-to-child syphilis transmission in Uganda and similar settings. What is already known on this topic: Congenital syphilis (CS) remains a major cause of preventable stillbirths and neonatal deaths, but the views of people delivering and receiving syphilis care in Uganda are poorly understood. What this study adds: Participants valued CS screening and treatment to protect infants, and facilitators included respectful counselling, phone follow-up and routine antenatal integration. Barriers included fear of injections, stigma, low male-partner involvement, weak information systems, stockouts of supplies, lack of CS confirmatory tests and caregivers refusing prolonged intravenous treatment for infants without symptoms. How this study might affect research, practice or policy: Programmes need community education, male engagement, patient tracing, stronger supply chains and integrated maternal-infant-partner care. Research should prioritise non-injectable, shorter duration infant treatments and affordable neonatal confirmatory testing. Summary: This qualitative study in Kampala, Uganda explored barriers and facilitators to maternal and congenital syphilis care. Key barriers included fear of painful injections, stigma, low male-partner involvement, and treatment refusal for asymptomatic infants. Facilitators included respectful counselling, phone follow-up, and integrating syphilis testing into routine antenatal care.

8 July 2026 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
JMJohan H. Melendez
Johan H. Melendez
AOAnnet A Onzia
Annet A Onzia
EMEmmanuel Mande
Emmanuel Mande
ATAdamaris Muniz Tirado
Adamaris Muniz Tirado
BDBrenda Dawa
Brenda Dawa
YMYukari C Manabe
Yukari C Manabe
Background: Pharyngeal Neisseria gonorrhoeae (phNG) infections are difficult to treat and contribute to antimicrobial resistance (AMR) in NG, but studies on phNG and differences with urogenital NG (uNG) are limited. Methods: Participants with urethral discharge syndrome were recruited at health clinics in Kampala, Uganda, between July 2020 and August 2023. Penile-meatal and pharyngeal swabs were cultured for NG and tested by nucleic acid amplification test (NAAT) for NG, Chlamydia trachomatis, and Mycoplasma genitalium. Paired uNG and phNG isolates were subjected to susceptibility testing and whole genome sequencing (WGS). Demographic and behavioral data were analyzed for correlates of uNG and phNG. Results: The participants’ (n = 411) median [IQR] age was 25 [22, 32] years; 16.7% (67/401) were living with HIV. By NAAT and/or culture, 273 (66.4%) participants were positive for uNG and 29 (7.1%) for phNG. Of those with uNG, 10.6% (29/273) were NAAT-positive for phNG; 69.0% (20/29) were culture-positive for phNG. All (n = 40) NG isolates were susceptible to cefixime and ceftriaxone and displayed intermediate resistance/resistance to ciprofloxacin, penicillin, and tetracycline; 8 displayed high-level azithromycin resistance. WGS showed that 52.6% (10/19) of participants had different strains at urethral and pharyngeal sites. Having different strains at 2 anatomical sites was more common in men self-reporting transactional sex (P = .019). Conclusions: phNG is common in Ugandan men with uNG, both displaying high rates of AMR. Different strains at the 2 anatomical sites were common, supporting the need for pharyngeal testing and phNG susceptibility testing as the pharynx is a critical site for AMR emergence.